评估使用taxan的缺血性结肠炎的安全风险:基于FDA不良事件报告系统的不成比例分析
Yufang Liao1, Yanbin Zeng1, Xiaorong Su1
1Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
Expert opinion on drug safety
|July 2, 2025
概括
塔克森化学疗法显著增加缺血性结肠炎 (IC) 的风险,这是一个严重的胃肠道疾病. 在接受纳税治疗的患者中,对IC的早期监测至关重要.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药物监督 药物监督 药物监督
背景情况:
- 缺血性结肠炎 (IC) 是一种罕见但严重的胃肠道疾病.
- 越来越多的IC病例报告在接受基于taxan的化疗的患者中.
- 纳税使用和IC之间的直接相关性仍然不清楚,需要进一步调查.
研究的目的:
- 评估与缺血性结肠炎有关的taxane化疗的安全问题.
- 评估分类剂的使用与IC的发展之间的潜在关联.
- 识别潜在的风险,并为临床实践提供有关高素诱导IC的信息.
主要方法:
- 进行了不成比例分析,包括报告几率比率 (ROR),比例报告比率 (PRR),贝叶斯信任传播神经网络 (BCPNN) 和多项马鱼缩小器 (MGPS).
- 使用了FDA不良事件报告系统 (FAERS) 数据库,涵盖了从2005年第一季度到2023年第二季度的数据.
- 采用统计方法检测出分类和IC之间的重要关联信号.
主要成果:
- 在各种分类物中检测到IC的显著信号,包括帕克利塔克塞尔,纳布-帕克利塔克塞尔和多塞塔克塞尔.
- 具体的ROR,PRR,BCPNN和MGPS值表明,使用分类剂和IC之间存在着显著的关联.
- 报告主要来自日本和美国,大约一半的IC病例在治疗开始后16天内发生.
结论:
- 塔克桑化学疗法可能会大幅增加患有缺血性结肠炎的风险.
- 对于接受基于税的治疗的患者来说,保持警的胃肠道监测是必不可少的.
- 需要进一步的临床验证来证实这些发现,并描述高风险人群.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
182
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
182
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K